Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Hussein Yassine, MD

    TitleAssistant Professor of Medicine
    SchoolKeck School of Medicine of USC
    AddressCSC 210
    Health Sciences Campus
    Los Angeles California 90089-9073
    Phone+1 323 442 1909
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Yassine is an Assistant Professor in the Department of Medicine, University of Southern California. The Yassine lab specializes in lipid metabolism, with an interest in Alzheimer's disease (AD).

      Carrying the APOE e4 allele is the strongest genetic risk factors for developing AD. Although only 20% of humans are APOE e4 carriers, these individuals account for up to 65% of all AD cases.

      Our research has been focused on the effect of APOE e4 on brain lipids in general and on the omega-3 fatty acid docosahexaenoic acid (DHA) in particular, and the mechanisms that regulate its brain delivery and metabolism.

      We demonstrated that lower levels of serum DHA associated with greater amyloid deposition in cognitively healthy older adults (JAMA Neurology, 2016), but not in patients with dementia (Alzheimer’s Research & Therapy, 2016). In patients with dementia, we identified an association between APOE e4 genotype and reduced levels of cerebrospinal fluid DHA after supplementation (Alzheimer’s Research & Therapy 2016).

      Using molecular studies, we identified that apoE apolipoproteins in cerebrospinal fluid have a decreased capacity to carry lipids by the ABCA-1 transporter, and that this lipid carrying capacity is lower in persons with mild cognitive impairment and Alzheimer’s compared to healthy controls (Journal of the American Heart Association, 2016).

      Using PET scans, we reported an increased incorporation coefficient for brain DHA in APOE e4 suggesting a deficit in brain DHA delivery in younger healthy APOE e4 carriers decades before the onset of AD. (Alzheimer’s Research & Therapy 2017).

      We hypothesize that apoE4 lipoproteins inefficiently transport lipids to brain areas involved in memory formation. Our long term goal is to demonstrate that AD pathology can be mitigated by enhancing apoE lipidation.

      More information can be found at www.yassinelab.com

      Collapse Biography 
      Collapse Awards and Honors
      Beirut Arab University, Beirut, Lebanon 2002Dean's Distinguished Student Medicine Day Award
      Beirut Arab University, Beirut, Lebanon 2003Dean's Honor List on graduation
      Case Western Reserve University, Cleveland, OH 2007Resident Teacher of the Year Award
      2009Department of Veterans Affairs VISN 18 Outstanding Research Award
      2009Presidential Poster Award, Endocrine Society

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Required Scholarly Project Mentor

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Jeffs JW, Ferdosi S, Yassine H, Borges CR. Ex vivo instability of glycated albumin: A role for autoxidative glycation. Arch Biochem Biophys. 2017 Sep 01; 629:36-42. PMID: 28712850.
        View in: PubMed
      2. Yassine H, Schneider LS. Lessons from the Multidomain Alzheimer Preventive Trial. Lancet Neurol. 2017 Aug; 16(8):585-586. PMID: 28721922.
        View in: PubMed
      3. Yassine H, Croteau E, Rawat V, Hibbeln JR, Rapoport SI, Cunnane SC, Umhau JC. DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA. Alzheimers Res Ther. 2017 Mar 23; 9(1):23. PMID: 28335828.
        View in: PubMed
      4. Yassine H, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E e4 Carriers: A Review. JAMA Neurol. 2017 Mar 01; 74(3):339-347. PMID: 28114437.
        View in: PubMed
      5. Mendoza S, Trenchevska O, King SM, Nelson RW, Nedelkov D, Krauss RM, Yassine H. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions. J Clin Lipidol. 2017 Jan - Feb; 11(1):224-233.e2. PMID: 28391889.
        View in: PubMed
      6. Yassine H, Feng Q, Azizkhanian I, Rawat V, Castor K, Fonteh AN, Harrington MG, Zheng L, Reed BR, DeCarli C, Jagust WJ, Chui HC. Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. JAMA Neurol. 2016 Oct 01; 73(10):1208-1216. PMID: 27532692.
        View in: PubMed
      7. Trenchevska O, Yassine H, Borges CR, Nelson RW, Nedelkov D. Development of quantitative mass spectrometric immunoassay for serum amyloid A. Biomarkers. 2016 Jul 22; 1-9. PMID: 27308834.
        View in: PubMed
      8. Yassine H, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016 Jun 30; 8:25. PMID: 27358067; PMCID: PMC4928349.
      9. Yassine H, Trenchevska O, Dong Z, Bashawri Y, Koska J, Reaven PD, Nelson RW, Nedelkov D. The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. Proteome Sci. 2016; 14:7. PMID: 27019641; PMCID: PMC4807542.
      10. Azizkhanian I, Trenchevska O, Bashawri Y, Hu J, Koska J, Reaven PD, Nelson RW, Nedelkov D, Yassine H. Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. J Clin Lipidol. 2016 Jul-Aug; 10(4):808-815. PMID: 27578111.
        View in: PubMed
      11. Koska J, Yassine H, Trenchevska O, Sinari S, Schwenke DC, Yen FT, Billheimer D, Nelson RW, Nedelkov D, Reaven PD. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. J Lipid Res. 2016 May; 57(5):894-905. PMID: 26945091; PMCID: PMC4847634 [Available on 05/01/17].
      12. Yassine H, Feng Q, Chiang J, Petrosspour LM, Fonteh AN, Chui HC, Harrington MG. ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease. J Am Heart Assoc. 2016 Feb 12; 5(2). PMID: 26873692; PMCID: PMC4802440.
      13. Yassine H, Trenchevska O, Ramrakhiani A, Parekh A, Koska J, Walker RW, Billheimer D, Reaven PD, Yen FT, Nelson RW, Goran MI, Nedelkov D. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. PLoS One. 2015; 10(12):e0144138. PMID: 26633899; PMCID: PMC4669142.
      14. Kimzey MJ, Kinsky OR, Yassine H, Tsaprailis G, Stump CS, Monks TJ, Lau SS. Site specific modification of the human plasma proteome by methylglyoxal. Toxicol Appl Pharmacol. 2015 Dec 01; 289(2):155-62. PMID: 26435215; PMCID: PMC4651758 [Available on 12/01/16].
      15. Yassine H, Trenchevska O, He H, Borges CR, Nedelkov D, Mack W, Kono N, Koska J, Reaven PD, Nelson RW. Serum amyloid a truncations in type 2 diabetes mellitus. PLoS One. 2015; 10(1):e0115320. PMID: 25607823; PMCID: PMC4301920.
      16. Yassine H, Jackson AM, Reaven PD, Nedelkov D, Nelson RW, Lau SS, Borchers CH. The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease. Transl Proteom. 2014 Dec 01; 4-5:18-24. PMID: 25705587.
        View in: PubMed
      17. Borges CR, Rehder DS, Jensen S, Schaab MR, Sherma ND, Yassine H, Nikolova B, Breburda C. Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions. Mol Cell Proteomics. 2014 Jul; 13(7):1890-9. PMID: 24736286; PMCID: PMC4083123.
      18. Yassine H, Belopolskaya A, Schall C, Stump CS, Lau SS, Reaven PD. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism. 2014 May; 63(5):727-34. PMID: 24636347; PMCID: PMC4014062.
      19. Yassine H, Jackson AM, Borges CR, Billheimer D, Koh H, Smith D, Reaven P, Lau SS, Borchers CH. The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins. Lipids Health Dis. 2014 Jan 08; 13:8. PMID: 24397693; PMCID: PMC3900256.
      20. Yassine H, Borges CR, Schaab MR, Billheimer D, Stump C, Reaven P, Lau SS, Nelson R. Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl. 2013 Aug; 7(7-8):528-40. PMID: 23696124; PMCID: PMC4029342.
      21. Kastoon T, Stump CS, Thomson SP, Yassine H. Erlotinib-associated exacerbation of hypothyroidism with pericardial tamponade. Endocr Pract. 2012 Sep-Oct; 18(5):e111-3. PMID: 22440982.
        View in: PubMed
      22. Yassine H, Kimzey MJ, Galligan MA, Gandolfi AJ, Stump CS, Lau SS. Adjusting for Urinary Creatinine Overestimates Arsenic Concentrations in Diabetics. Cardiorenal Med. 2012 Feb; 2(1):26-32. PMID: 22493600.
        View in: PubMed
      23. Yassine H, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF. Effect of glucose or fat challenge on aspirin resistance in diabetes. Int J Endocrinol. 2010; 2010:820876. PMID: 21318184; PMCID: PMC3034931.
      24. Kimzey MJ, Yassine H, Riepel BM, Tsaprailis G, Monks TJ, Lau SS. New site(s) of methylglyoxal-modified human serum albumin, identified by multiple reaction monitoring, alter warfarin binding and prostaglandin metabolism. Chem Biol Interact. 2011 Jun 30; 192(1-2):122-8. PMID: 20934417; PMCID: PMC3050118.
      25. Yassine H, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF. Clinical determinants of aspirin resistance in diabetes. Diabetes Res Clin Pract. 2010 Oct; 90(1):e19-21. PMID: 20719400; PMCID: PMC2962939.
      26. Yassine H, Marchetti CM, Krishnan RK, Vrobel TR, Gonzalez F, Kirwan JP. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults--a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2009 Jan; 64(1):90-5. PMID: 19164269; PMCID: PMC2691195.